sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY June 2015 | Archived Issues

P & T Committee Approvals, FDA Warning About Diabetes Drugs

Pharmacy Focus

See highlights of the April meeting of the Pharmacy and Therapeutics Committee. Also, the U.S. Food and Drug Administration has released a warning that the Type 2 diabetes medications canagliflozin, dapagliflozin and empagliflozin may lead to acidosis, including ketoacidosis.


Mark Your Calendar


Surgery Grand Rounds

Click the "read more" to see information about upcoming Surgery Grand Rounds.


Grand Rounds

Click here to view a schedule of all upcoming grand rounds.


Surgery Scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

P & T Committee Approvals, FDA Warning About Diabetes Drugs

Pharmacy Focus

Highlights of the April meeting of the Pharmacy and Therapeutics Committee are summarized in the PDF link below. Also, the U.S. Food and Drug Administration has released a warning that the Type 2 diabetes medications canagliflozin, dapagliflozin and empagliflozin may lead to acidosis, including ketoacidosis.

P&T Approvals - April 2015 (PDF)

FDA: Certain Diabetes Drugs May Lead to Acidosis

The FDA has released a warning that the Type 2 diabetes medications canagliflozin, dapagliflozin and empagliflozin may lead to acidosis, including ketoacidosis. Ketoacidosis is a serious condition in which the body produces high levels of blood acids called ketones that may require hospitalization.

The FDA is not making any changes to the prescribing information for this class of drugs, known as sodium glucose cotransporter-2 (SGLT2) inhibitors. However, it is requesting that patients be made aware of symptoms such as difficulty breathing, nausea or vomiting, abdominal pain, confusion and unusual fatigue or sleepiness.

For more information, click here.